ClinicalTrials.gg
RecruitingNCT06291597VapALERTUpdated Mar 4, 2024

Vaping Adverse Lung and Heart Events Cohort

An observational study in Vaping and Electronic Cigarette Use, sponsored by Laval University. Recruiting at 1 site in Canada. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Laval University · Observational

How we know

From the registry’s dates

  • Started Oct 2021; still recruiting 5 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Vaping with a site in Canada — 6 open to participants now, 8 under way, 1 of them phase 3. Vaping · Canada.

Started
2021
the only one that year
Observational
3 of 13
3 open now
Registered
8th of 13
by date
Lead sponsor
1 of 13
Laval University

Among the 13 studies in Vaping with a site in Canada, this one is the only one that started in 2021, is one of 3 observational ones, and was the 8th registered.

Vaping

404 studies on the registry are indexed under Vaping; 97 are open to participants now.

Browse Vaping studies →

Open to participants now

6 of the 13 studies in Vaping with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 65 Vaping studies recruiting now, 33 (51%) set no upper age limit and 31 (48%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Vaping with a site in Canada, or all of them as a file.
02

Study summary

This prospective study assesses the pulmonary and cardiovascular effets of vaping in adult electronic cigarette users with biannual visits and a 5-year follow-up.

Read the detailed description

Daily vaping device users will be recruited in the Quebec City metropolitan area. Subjects will be asked to perform pulmonary function tests (spirometry, oscillometry, plethysmography, methacholine provocation) every 6 months for a 5-year follow up. Subjects will also answer a questionnaire assessing their vaping, tobacco and cannabis smoking habits, as well as their perceived respiratory symptoms. Blood draws and sputum inductions will be performed for cell counts and to measure inflammation markers.

03

Conditions studied

  • Vaping
  • Electronic Cigarette Use

Browse trials for

Keywords

  • Vaping
  • Vape
  • Electronic cigarette
  • Electronic and vaping acute lung injury
  • EVALI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

We seek to recruit 250 volunteers from the community with twice-a-year visits for a 5-year follow-up. We will recruit healthy volunteers as well as volunteers who have been previously diagnosed with chronic illness.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • Daily electronic cigarette user
  • No respiratory infection in the 4 weeks before a visit

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breast-feeding.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Daily electronic cigarette users

    Participants must use their vaping device everyday at time of enrollment.

    Other: Vaping

Interventions

  • OtherVaping

    Participants use their vaping products at their own discretion and their intake is monitored via questionnaires.

06

What researchers measure

Primary outcomes

  1. Number of participants who vape daily with impaired lung volumes.

    Participants will perform plethysmography assessments to measure changes in lung volumes. Data will be expressed as a percentage of predicted values.

    Time frame: Every 6 months for 5 years

  2. Number of participants who vape daily with impaired lung diffusion capacity.

    Participants will perform diffusion capacity of the lung for carbon monoxide (DLCO) measures to assess changes in lung diffusion capacity. Data will be expressed as a percentage of predicted values.

    Time frame: Every 6 months for 5 years

  3. Number of participants who vape daily with impaired spirometry.

    Participants will perform spirometry tests measures to assess changes in forced expiratory lung volumes. Data will be expressed as a percentage of predicted values.

    Time frame: Every 6 months for 5 years

  4. Number of participants who vape daily with airway hyperresponsiveness.

    Participants will perform methacholine provocation challenge measures to assess changes in airway hyperresponsiveness. Data will be expressed as the methacholine concentration inducing a fall of 20% of forced expiratory volume in the first second assessed (PC20).

    Time frame: Every 6 months for 5 years

  5. Number of participants who vape daily with changes in blood cell count.

    Participants will perform a blood draw to assess blood cell count. Data will be expressed as a percentage of eosinophils, neutrophils, macrophages and lymphocytes of the total cell count.

    Time frame: Every 6 months for 5 years

  6. Number of participants who vape daily with changes in sputum cell count.

    Participants will perform sputum inductions to assess cell count in the sputum. Data will be expressed as a percentage of eosinophils, neutrophils, macrophages and lymphocytes of the total cell count.

    Time frame: Every 6 months for 5 years

  7. Vaping, tobacco and cannabis smoking habits of participants.

    Participants will complete questionnaires assessing their vaping habits, tobacco smoking and cannabis smoking history.

    Time frame: Every 3 months for 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2021 (actual). Primary completion is estimated for Dec 2031, 122 months after the start.

Of 32 observational studies under Vaping, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 46. This study's planned 122 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 7, 2023
First posted
Mar 4, 2024
StartActual
Oct 14, 2021
Primary completionEst.
Dec 2031
CompletionEst.
Jun 2032
Last update
Mar 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06291597
Lead sponsor
Laval University
Collaborators
Ministere de la Sante et des Services Sociaux
Responsible party
Sponsor
First posted
Mar 4, 2024
Start date
Oct 14, 2021
Primary completion
Dec 2031 (estimated)
Completion
Jun 2032 (estimated)
Last update
Mar 4, 2024

Study contacts

Ariane Lechasseur, PhD
Contact
ariane.lechasseur@criucpq.ulaval.ca
418-656-8711 ext. 2652
Mathieu C Morissette, PhD
Contact
mathieu.morissette@criucpq.ulaval.ca
418-656-8711 ext. 5394
Mathieu C Morissette, PhD
principal investigator · Laval University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion